AR102181A1 - Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv - Google Patents

Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv

Info

Publication number
AR102181A1
AR102181A1 ARP150103215A ARP150103215A AR102181A1 AR 102181 A1 AR102181 A1 AR 102181A1 AR P150103215 A ARP150103215 A AR P150103215A AR P150103215 A ARP150103215 A AR P150103215A AR 102181 A1 AR102181 A1 AR 102181A1
Authority
AR
Argentina
Prior art keywords
alkenyl
substituted
alkyl
rsv infection
pirrolopiridine
Prior art date
Application number
ARP150103215A
Other languages
English (en)
Inventor
Ward Simon
Paradowski Michael
Mathews Neil
Lunn Graham
Miguel Gascon Simorte Jose
Cockerill Stuart
Original Assignee
Re:Viral Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR102181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Re:Viral Ltd filed Critical Re:Viral Ltd
Publication of AR102181A1 publication Critical patent/AR102181A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bencimidazoles de la fórmula (1), en donde: uno de X e Y es un átomo de N o un átomo de C sustituido, y el otro es CH; L es un enlace sencillo, C₁₋₃ alquileno, C₂₋₃ alquenileno o C₂₋₃ alquinileno; R¹ es C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, cicloalquilo de 3 a 10 miembros, heterociclilo de 5 a 10 miembros o heteroarilo de 5 a 12 miembros, cada uno de los cuales es no sustituido o sustituido; Z es halo, C₁₋₆ haloalquilo, nitro, -CN, -N(R²)₂, -OR², -SR², -S(=O)R², o -S(=O)₂R²; cada R² es independientemente hidrógeno, C₁₋₆ alquilo, C₂₋₆ alquenilo o C₂₋₆ alquinilo, en donde dichos grupos alquilo, alquenilo y alquinilo son no sustituido o sustituido; y m es 0 ó 1; y la sal farmacéuticamente aceptable del mismo son inhibidores de RSV y pueden por lo tanto ser utilizados para tratar o prevenir una infección por RSV.
ARP150103215A 2014-10-07 2015-10-06 Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv AR102181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
AR102181A1 true AR102181A1 (es) 2017-02-08

Family

ID=51946966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103215A AR102181A1 (es) 2014-10-07 2015-10-06 Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv

Country Status (30)

Country Link
US (1) US10106539B2 (es)
EP (1) EP3204375B1 (es)
JP (1) JP6695334B2 (es)
KR (2) KR102561796B1 (es)
CN (1) CN107108557B (es)
AR (1) AR102181A1 (es)
AU (1) AU2015329778B2 (es)
BR (1) BR112017007311B1 (es)
CA (1) CA2963740C (es)
CL (1) CL2017000839A1 (es)
CO (1) CO2017004603A2 (es)
CY (1) CY1121564T1 (es)
DK (1) DK3204375T3 (es)
ES (1) ES2718976T3 (es)
GB (1) GB201417707D0 (es)
HR (1) HRP20190808T1 (es)
HU (1) HUE043553T2 (es)
LT (1) LT3204375T (es)
MX (1) MX2017004425A (es)
NZ (1) NZ731323A (es)
PE (1) PE20170949A1 (es)
PL (1) PL3204375T3 (es)
PT (1) PT3204375T (es)
RS (1) RS58706B1 (es)
RU (1) RU2734248C2 (es)
SG (1) SG11201702766YA (es)
SI (1) SI3204375T1 (es)
TR (1) TR201903362T4 (es)
TW (1) TWI718107B (es)
WO (1) WO2016055780A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821649T3 (es) * 2015-06-08 2021-04-27 Shangdong Danhong Pharmaceutical Co Ltd Método para preparar derivados de imidazol e intermedios de los mismos y formas cristalinas
PT3494110T (pt) 2016-08-04 2021-06-03 Reviral Ltd Derivados de pirimidina e sua utilização no tratamento ou prevenção de uma infeção pelo vírus sincicial respiratório
GB201711704D0 (en) 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
RU2184735C2 (ru) * 1998-01-23 2002-07-10 Санкио Компани, Лимитед Производные спиропиперидина, лекарственное средство, способ профилактики или лечения
PT1196408E (pt) * 1999-06-28 2005-01-31 Janssen Pharmaceutica Nv Inibidores da replicacao do virus sincicial respiratorio
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
TWI598351B (zh) 2012-10-16 2017-09-11 健生科學愛爾蘭無限公司 Rsv抗病毒化合物
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
EP2997028A1 (en) * 2013-05-14 2016-03-23 F.Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
CN105408330A (zh) * 2013-08-12 2016-03-16 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
RU2016105970A (ru) * 2013-08-12 2017-09-19 Ф. Хоффманн-Ля Рош Аг Новые азаоксоиндолы для лечения и профилактики инфекции респираторного синцитиального вируса
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
WO2015022301A1 (en) * 2013-08-15 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌
CN105431419A (zh) * 2013-08-15 2016-03-23 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚

Also Published As

Publication number Publication date
WO2016055780A1 (en) 2016-04-14
HUE043553T2 (hu) 2019-09-30
CA2963740A1 (en) 2016-04-14
PE20170949A1 (es) 2017-07-13
BR112017007311B1 (pt) 2022-11-22
KR102561796B1 (ko) 2023-07-31
CN107108557A (zh) 2017-08-29
GB201417707D0 (en) 2014-11-19
AU2015329778B2 (en) 2020-04-23
RS58706B1 (sr) 2019-06-28
HRP20190808T1 (hr) 2019-08-23
PT3204375T (pt) 2019-04-01
TWI718107B (zh) 2021-02-11
SI3204375T1 (sl) 2019-05-31
BR112017007311A2 (pt) 2017-12-19
CA2963740C (en) 2022-11-29
RU2017113026A3 (es) 2019-03-22
CO2017004603A2 (es) 2017-10-31
SG11201702766YA (en) 2017-05-30
KR20170066577A (ko) 2017-06-14
TW201625583A (zh) 2016-07-16
US20170305908A1 (en) 2017-10-26
US10106539B2 (en) 2018-10-23
LT3204375T (lt) 2019-05-10
CN107108557B (zh) 2020-11-10
ES2718976T3 (es) 2019-07-05
PL3204375T3 (pl) 2019-06-28
AU2015329778A1 (en) 2017-05-04
RU2017113026A (ru) 2018-11-13
TR201903362T4 (tr) 2019-04-22
EP3204375A1 (en) 2017-08-16
CL2017000839A1 (es) 2017-10-13
JP2017530992A (ja) 2017-10-19
KR20230116097A (ko) 2023-08-03
AU2015329778A8 (en) 2017-05-18
JP6695334B2 (ja) 2020-05-20
DK3204375T3 (en) 2019-04-01
MX2017004425A (es) 2017-10-11
RU2734248C2 (ru) 2020-10-13
NZ731323A (en) 2022-09-30
CY1121564T1 (el) 2020-05-29
EP3204375B1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
AR102181A1 (es) Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
SV2016005290A (es) Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih
PE20191461A1 (es) Compuestos amida para el tratamiento del vih
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
ECSP20029790A (es) Compuestos moduladores de sting y métodos de elaboración y uso
CY1120325T1 (el) Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR103680A1 (es) Inhibidores selectivos de bace1
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
SV2017005381A (es) Compuestos de imidazopiridazina
PE20160689A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
NI201800071A (es) Compuestos de isoindol
PE20171335A1 (es) Inhibidores de gingipaina de lisina
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
ECSP16096831A (es) Derivados de naftiridinadiona
CO2019007186A2 (es) Moduladores de ror gamma (rorγ)

Legal Events

Date Code Title Description
FC Refusal